Nkarta Inc. (NKTX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
NKTX Chart
Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space.
Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade
Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter and year ended March 31, 2025.
Nkarta Inc. Dividends
Nkarta Inc. Earnings
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 19 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 9 Aug 2024 Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 19 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 9 Aug 2024 Date | | - Cons. EPS | - EPS |
Nkarta Inc. (NKTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nkarta Inc. ever had a stock split?
Nkarta Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Paul J. Hastings CEO | NASDAQ (NGS) Exchange | 65487U108 Cusip |
| US Country | 157 Employees | - Last Dividend | - Last Split | 10 Jul 2020 IPO Date |
Overview
Nkarta, Inc. is a pioneering biopharmaceutical company that operates in the clinical-stage, focusing on the development and commercialization of innovative natural killer (NK) cell therapies. These therapies are designed for the treatment of cancer as well as autoimmune diseases. The company employs cutting-edge technology to harness the innate power of NK cells, combining them with chimeric antigen receptors (CARs) to target and eliminate cancer cells more effectively. Founded in 2015, Nkarta has established itself in South San Francisco, California, at the forefront of cellular therapy research. In collaboration with CRISPR Therapeutics AG, Nkarta continues to advance its research and development efforts, aiming to bring new therapeutic options to patients with limited treatment opportunities.
Products and Services
NKX019: This leading-edge CAR NK cell therapy targets the CD19 antigen, which is commonly expressed on the surface of B cells implicated in various lymphomas and leukemias. Currently, NKX019 is undergoing Phase 1 clinical trials to evaluate its efficacy and safety in treating relapsed/refractory non-Hodgkin lymphoma (r/r NHL). The therapy represents a novel approach in harnessing the natural cytotoxic abilities of NK cells against cancer cells.
NKX101: Another innovative product candidate from Nkarta is NKX101, which is designed to attack cells displaying NKG2D ligands. These ligands are typically expressed on the surface of tumor cells, making NKX101 a potential therapy for relapsed/refractory acute myeloid leukemia (r/r AML), high-risk myelodysplastic syndromes, and solid tumors. NKX101 leverages the potent antitumor activity of NK cells, activating them through the NKG2D receptor — a recognized mediator of NK cell cytotoxicity.
NKX070: Focused on targeting the CD70 tumor antigen, NKX070 is Nkarta's response to the need for effective treatments against both solid and liquid tumors. By targeting CD70, an antigen expressed in various cancers, NKX070 aims to provide a broad-spectrum antitumor therapy, leveraging the innate and adaptive immune systems to eradicate cancer cells.
NK+T Cell Therapy: Expanding the scope of cellular immunotherapy, Nkarta is developing therapies that combine the unique attributes of NK cells with T cells. This approach aims to create a dual-action therapy capable of addressing oncology, autoimmune diseases, and infectious diseases. By uniting the fast-acting, innate response of NK cells with the adaptability and memory of T cells, Nkarta envisions creating a more versatile and potentially more effective treatment option.
Contact Information
